11 research outputs found
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria
Early Sentence Productions Of 5-Year-Old Children Who Use Augmentative And Alternative Communication
Four 5-year-old children with receptive language within normal limits and who required augmentative and alternative communication (AAC) received instruction in producing six different semantic-syntactic structures (three treatment and three generalization targets). Participants accessed single-meaning graphic symbols using an AAC app on an iPad to create their messages. A single-case, multiple probe across targets design was used to assess the progress of each participant, and supplementary measures including self-corrections and error types were analyzed. Three participants mastered all six targets during baseline, with a fourth mastering four of six targets in baseline. In contrast to prior reports, findings from the current study indicate that some young children who require AAC can learn to produce rule-based messages using single-meaning graphic symbols rapidly and with minimal instruction. Careful attention to participant characteristics and task demands are required in future research to further refine approaches to teaching young participants to produce rule-based graphic symbol messages
Feasibility study on the production and marketing of WeraCrepida Inc.
When people talk about the foot wear industry, leather is the first thing that comes into their minds. This is due to the fact that leather footwear industry has been in the market longer than its synthetic counterparts like rubber and plastic. But as the price of leather raw material increased in time, manufacturers ventured into making use of other materials. The use of plastic and rubber definitely comes out cheaper as compared to leather but the group thought of manufacturing disposable slippers made of feelon because it would come out even cheaper as compared to not only leather but also rubber and plastic.
This feasibility study was conducted to determine the level of acceptability of producing disposable slippers made of feelon in the selected accommodation establishments in Metro Manila particularly standard and economy class hotels and motels/pensions. The universe of the study is composed of the selected accredited accommodation establishments because these establishments are required by the Department of Tourism (Hotel Code) to provide certain amenities to be accredited. Disposable slippers made of feelon being an alternative amenity may be included as part or such requirement. These establishments may also provide this alternative amenity while working within their budget or as a cost cutting expense. Several other objectives falling under the five aspects of the study namely: market study, technical study, management and legal study, financial study and the socio-economic study were also determined.
The group made use of the descriptive type of research. Both qualitative and quantitative data were utilized in the study. Primary data was acquired through the distribution of survey questionnaires. Secondary data was acquired through research in various places like the De La Salle University Library, Center for Research and Industry, and the Philippine Chamber of Commerce and Industry. Comments of the respondents while the group was conducting the survey were also considered as part of secondary data.
The group gave out questionnaires to purchasing department managers, operations department managers, and housekeeping executives of selected accredited accommodation establishments in Metro Manila. The group, upon receiving the results of the survey, tallied the response that was given.
For the results of the market study, the proponents came to verify that there is indeed a current demand for disposable slippers made of feelon in selected accommodation establishments in Metro Manila. In particular, the group\u27s primary target market consists of DOH accredited economy and standard class hotels, motels/pensions. The acceptable price is P 10 per pair. Clear plastic will be used for packaging the product so the silk screened logo of the company on the slippers will be visible. In order to sell the product effectively, personal selling would be employed.
The proponents would not encounter difficulty in producing their product, since they have developed the skill and acquired the knowledge in order to manufacture their minimum monthly demand of 756 pairs. This figure was obtained after a time and motion study that also forecasted that it would take 12 mins and 41 seconds to manufacture 1 pair of disposable slippers.
The management and legal study made it possible for the proponents to give justification in engaging in a corporate for of ownership that shall be called WeraCrepida, Inc. This is to commence on October 7, 1995 until the 2nd week of July 1996. Since there are 9 incorporators, the corporation shall have an initial capital requirement of P 13,500.
The initial capital requirement is sufficient for covering all costs and expenses needed for the business operations. It would allow the proponents to generate a profit as projected by the financial statements in the financial study.
Since business should not only be put up for profit but also for the benefit of society, WeraCrepida, Inc. provides its target market with an alternative amenity for their particular establishment. It also employs 9 individuals thus compensating them with wages.
All the objectives of each study served as basis for the proponents to conclude that disposable slippers made of feelon is a feasible product
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)
CaMKK2 signals through AMPK-dependent and AMPK-independent
pathways
to trigger cellular outputs including proliferation, differentiation,
and migration, resulting in changes to metabolism, bone mass accrual,
neuronal function, hematopoiesis, and immunity. CAMKK2 is upregulated
in tumors including hepatocellular carcinoma, prostate, breast, and
gastric cancer, and genetic deletion in myeloid cells results in increased
antitumor immunity in several syngeneic models. Validation of the
biological roles of CaMKK2 has relied on genetic deletion or small
molecule inhibitors with activity against several biological targets.
We sought to generate selective inhibitors and degraders to understand
the biological impact of inhibiting catalytic activity and scaffolding
and the potential therapeutic benefits of targeting CaMKK2. We report
herein selective, ligand-efficient inhibitors and ligand-directed
degraders of CaMKK2 that were used to probe immune and tumor intrinsic
biology. These molecules provide two distinct strategies for ablating
CaMKK2 signaling in vitro and in vivo
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)
CaMKK2 signals through AMPK-dependent and AMPK-independent
pathways
to trigger cellular outputs including proliferation, differentiation,
and migration, resulting in changes to metabolism, bone mass accrual,
neuronal function, hematopoiesis, and immunity. CAMKK2 is upregulated
in tumors including hepatocellular carcinoma, prostate, breast, and
gastric cancer, and genetic deletion in myeloid cells results in increased
antitumor immunity in several syngeneic models. Validation of the
biological roles of CaMKK2 has relied on genetic deletion or small
molecule inhibitors with activity against several biological targets.
We sought to generate selective inhibitors and degraders to understand
the biological impact of inhibiting catalytic activity and scaffolding
and the potential therapeutic benefits of targeting CaMKK2. We report
herein selective, ligand-efficient inhibitors and ligand-directed
degraders of CaMKK2 that were used to probe immune and tumor intrinsic
biology. These molecules provide two distinct strategies for ablating
CaMKK2 signaling in vitro and in vivo
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)
CaMKK2 signals through AMPK-dependent and AMPK-independent
pathways
to trigger cellular outputs including proliferation, differentiation,
and migration, resulting in changes to metabolism, bone mass accrual,
neuronal function, hematopoiesis, and immunity. CAMKK2 is upregulated
in tumors including hepatocellular carcinoma, prostate, breast, and
gastric cancer, and genetic deletion in myeloid cells results in increased
antitumor immunity in several syngeneic models. Validation of the
biological roles of CaMKK2 has relied on genetic deletion or small
molecule inhibitors with activity against several biological targets.
We sought to generate selective inhibitors and degraders to understand
the biological impact of inhibiting catalytic activity and scaffolding
and the potential therapeutic benefits of targeting CaMKK2. We report
herein selective, ligand-efficient inhibitors and ligand-directed
degraders of CaMKK2 that were used to probe immune and tumor intrinsic
biology. These molecules provide two distinct strategies for ablating
CaMKK2 signaling in vitro and in vivo
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)
CaMKK2 signals through AMPK-dependent and AMPK-independent
pathways
to trigger cellular outputs including proliferation, differentiation,
and migration, resulting in changes to metabolism, bone mass accrual,
neuronal function, hematopoiesis, and immunity. CAMKK2 is upregulated
in tumors including hepatocellular carcinoma, prostate, breast, and
gastric cancer, and genetic deletion in myeloid cells results in increased
antitumor immunity in several syngeneic models. Validation of the
biological roles of CaMKK2 has relied on genetic deletion or small
molecule inhibitors with activity against several biological targets.
We sought to generate selective inhibitors and degraders to understand
the biological impact of inhibiting catalytic activity and scaffolding
and the potential therapeutic benefits of targeting CaMKK2. We report
herein selective, ligand-efficient inhibitors and ligand-directed
degraders of CaMKK2 that were used to probe immune and tumor intrinsic
biology. These molecules provide two distinct strategies for ablating
CaMKK2 signaling in vitro and in vivo
Recommended from our members
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria